antibiot
overus
typic
stem
use
drug
treat
nonbacteri
infect
sever
global
health
econom
consequ
includ
emerg
antibioticresist
bacteria
antibiot
underus
due
delay
miss
diagnosi
also
common
bacteri
infect
may
result
prolong
diseas
state
medic
complic
major
caus
antibiot
overus
underus
difficulti
distinguish
bacteri
nonbacteri
mostli
viral
etiolog
routin
use
microbiolog
diagnost
test
cultur
serolog
recent
nucleic
acid
base
test
eg
rtpcr
assist
clinician
etiolog
determin
underli
infecti
process
sever
challeng
remain
includ
pathogen
detect
case
infect
site
readili
access
eg
pneumonia
unknown
eg
fever
without
sourc
ii
time
microbiolog
laboratori
result
may
lengthi
hour
day
iii
interpret
whether
detect
bacteria
diseas
caus
agent
mere
colon
iv
identif
viru
preclud
possibl
undetect
bacteria
may
caus
underli
ill
ie
case
mix
infect
viru
bacteria
approach
potenti
address
challeng
reli
monitor
host
immunerespons
infect
rather
direct
pathogen
detect
recent
studi
examin
hostrna
signatur
respons
differ
infect
show
promis
result
howev
quantit
rapid
measur
within
minut
multipl
hostrna
clinic
set
remain
technic
challeng
especi
pointofcar
antibiot
prescript
made
circul
hostprotein
attract
altern
rapidli
measur
point
need
protein
routin
use
support
diagnosi
infect
includ
procalcitonin
creactiv
protein
crp
howev
marker
sensit
interpati
variabl
includ
time
symptom
onset
clinic
syndrom
pathogen
speci
exampl
multipl
studi
found
procalcitonin
valuabl
guid
antimicrobi
therapi
durat
predict
diseas
sever
howev
diagnost
accuraci
detect
bacteri
etiolog
case
sepsi
pneumonia
challeng
elev
crp
level
suggest
bacteri
infect
similar
level
may
observ
patient
viral
strain
eg
adenoviru
influenza
inflammatori
diseas
rise
quickli
respons
bacteri
trigger
util
dampen
limit
window
opportun
measur
due
rapid
decay
within
approxim
hour
improv
perform
individu
hostprotein
combin
sever
protein
singl
predict
score
propos
howev
date
studi
combin
provid
limitedtomoder
diagnost
improv
individu
protein
may
explain
predomin
focu
bacterialinduc
protein
eg
procalcitonin
saa
crp
strem
share
biolog
pathway
thu
inher
sensit
factor
therefor
reason
combin
unrel
hostprotein
particip
differ
pathway
may
improv
diagnost
accuraci
particular
inclus
new
hostprotein
upregul
viral
infect
may
innov
complement
bacteriallyinduc
protein
current
clinic
use
accordingli
aim
present
studi
threefold
perform
largescal
screen
novel
tradit
hostprotein
integr
find
comput
signatur
accur
diagnosi
acut
bacteri
mix
versu
viral
infect
valid
signatur
independ
cohort
patient
prospect
recruit
patient
august
novemb
hillelyaff
bnaizion
medic
center
israel
studi
approv
hillelyaff
medic
center
institut
review
board
approv
id
bnaizion
medic
center
institut
review
board
approv
id
studi
conduct
accord
guidelin
recommend
good
clinic
practic
declar
helsinki
written
inform
consent
obtain
particip
legal
guardian
applic
pediatr
patient
year
recruit
pediatr
emerg
depart
pediatr
ward
surgic
depart
adult
year
emerg
depart
intern
medicin
depart
surgic
depart
inclus
criteria
infecti
diseas
cohort
includ
clinic
suspicion
acut
infecti
diseas
peak
fever
sinc
onset
symptom
durat
symptom
day
inclus
criteria
control
group
includ
clinic
impress
noninfecti
diseas
eg
trauma
stroke
myocardi
infarct
healthi
subject
exclus
criteria
includ
evid
acut
infect
two
week
preced
enrol
congenit
immun
defici
treatment
immunosuppress
immunomodulatori
therapi
activ
malign
human
immunodefici
viru
hiv
hepat
bc
viru
infect
fig
importantli
order
enabl
broad
generaliz
antibiot
treatment
exclus
criterion
patient
follow
baselin
variabl
record
demograph
medic
histori
physic
examin
complet
blood
count
obtain
enrol
chemistri
panel
nasal
swab
obtain
microbiolog
investig
includ
two
multiplexpcr
diagnost
assay
seeplex
n
viral
strain
seeplex
n
six
bacteri
strain
blood
sampl
obtain
hostprotein
measur
addit
sampl
obtain
deem
appropri
physician
eg
urin
n
stool
n
blood
n
sampl
case
suspect
urinari
tract
infect
uti
gastroenter
gi
bacteremia
respect
data
radiolog
test
obtain
discret
physician
eg
chest
xray
suspect
lower
respiratori
tract
infect
lrti
thirti
day
enrol
diseas
cours
respons
treatment
record
determin
infecti
etiolog
creat
rigor
expert
panel
refer
standard
follow
broadli
accept
recommend
standard
report
diagnost
accuraci
stard
nh
health
technolog
assess
nhshta
evalu
diagnost
test
first
perform
thorough
clinic
microbiolog
investig
patient
describ
follow
review
data
collect
throughout
diseas
cours
panel
three
physician
adult
patient
panel
includ
attend
physician
two
infecti
diseas
specialist
children
includ
attend
pediatrician
infecti
diseas
expert
senior
attend
pediatrician
panel
member
assign
one
follow
diagnost
label
patient
bacteri
ii
viral
iii
appar
infecti
diseas
healthi
control
iv
indetermin
patient
diagnos
panel
mix
infect
bacteria
viru
label
bacteri
manag
similarli
panel
member
blind
label
peer
prevent
group
pressur
influenti
person
bia
recommend
nhshta
importantli
blind
result
signatur
final
diagnosi
determin
panel
major
ie
least
two
three
panel
member
assign
label
fig
examin
generaliz
result
recommend
examin
whether
altern
refer
standard
strategi
affect
perform
thu
two
addit
strategi
appli
unanim
subcohort
patient
assign
label
three
panel
member
ii
microbiolog
confirm
subcohort
bacteri
label
patient
unanim
diagnos
three
panel
member
one
follow
microbiolog
confirm
bacteremia
posit
blood
cultur
bacteri
mening
posit
csf
cultur
lower
uti
posit
urin
cultur
upper
uti
posit
urin
cultur
ultrasound
demonstr
renal
involv
peritonsillar
abscess
proven
surgic
explor
computer
tomographi
viral
label
patient
unanim
diagnos
panel
member
least
one
laboratori
detect
viru
venou
blood
sampl
store
hour
subsequ
fraction
plasma
serum
total
leukocyt
store
nasal
swab
stool
sampl
store
hour
subsequ
transport
certifi
servic
laboratori
multiplex
pcr
screen
phase
hostprotein
measur
use
enzymelink
immunosorbentassay
elisa
luminex
proteinarray
flowcytometri
three
protein
use
final
signatur
measur
follow
crp
use
either
roch
trail
use
commerci
elisa
kit
meme
diagnost
primari
analysi
base
auc
sensit
tpp
specif
tnn
posit
likelihood
ratio
lr
sensit
neg
likelihood
ratio
specif
diagnost
odd
ratio
dor
p
n
tp
tn
correspond
posit
bacteri
patient
neg
viral
patient
true
posit
true
neg
respect
sampl
size
calcul
present
data
half
patient
studi
randomli
assign
trainingset
use
protein
screen
model
develop
remain
half
mutual
exclus
validationset
use
assess
model
perform
importantli
none
validationset
patient
use
train
algorithm
select
protein
fig
multinomi
logist
regress
model
use
integr
level
multipl
protein
bacteri
likelihood
score
patient
whose
probabl
bacteri
infect
intermedi
flag
use
term
equivoc
immun
respons
describ
patient
profil
border
bacteri
viral
hostrespons
statist
analysi
perform
use
matlab
mathwork
final
diagnosi
attain
patient
fig
addit
patient
label
indetermin
diseas
etiolog
could
establish
tabl
cohort
balanc
respect
gender
femal
male
includ
pediatr
patient
year
adult
year
patient
present
wide
rang
clinic
syndrom
eg
rti
uti
gi
maxim
temperatur
time
symptom
onset
day
comorbid
medic
tabl
data
altogeth
pathogen
speci
detect
respons
major
acut
infect
western
world
data
gener
overview
process
develop
train
valid
multivari
logist
model
depict
fig
perform
systemat
literatur
bioinformat
screen
identifi
protein
may
differenti
express
respons
infect
data
next
protein
candid
measur
patient
trainingset
viral
bacteri
wilcoxon
ranksum
pvalu
use
screen
protein
exhibit
statist
signific
differenti
express
evalu
addit
patient
viral
bacteri
screen
use
ttest
p
bonferroni
correct
multipl
hypothesi
test
enabl
downselect
protein
fig
multipl
featur
select
algorithm
comput
model
evalu
identifi
optim
combin
final
protein
data
discrimin
signatur
auc
attain
trainingset
use
logist
regress
integr
level
follow
viral
bacterialinduc
protein
fig
trail
member
tumor
necrosi
factor
famili
implic
program
cell
death
small
cytokin
implic
multipl
cellular
process
includ
chemotaxi
cell
growth
inhibit
crp
acut
phase
protein
divers
role
tissu
injuri
infect
inflamm
process
evalu
signatur
perform
use
independ
validationset
neither
use
screen
hostprotein
develop
signatur
auc
distinguish
bacteri
viral
infect
validationset
similar
result
obtain
use
crossvalid
entir
cohort
auc
support
signatur
generaliz
tabl
signatur
significantli
outperform
individu
protein
evalu
screen
phase
p
next
use
signatur
distinguish
infecti
bacteri
viral
noninfecti
control
yield
auc
validationset
evalu
use
crossvalid
confirm
result
auc
outperform
individu
protein
p
examin
whether
signatur
maintain
steadi
perform
despit
patienttopati
variabl
perform
subgroup
analys
signatur
robustli
distinguish
bacteri
viral
infect
auc
across
wide
rang
patient
characterist
includ
age
clinic
syndrom
time
symptom
onset
maxim
temperatur
comorbid
pathogen
speci
fig
data
next
analyz
degre
altern
strategi
determin
refer
standard
affect
perform
two
strategi
appli
first
unanim
subcohort
wherebi
patient
diagnosi
unanim
assign
three
panel
expert
ntotal
nbacteri
nviral
ncontrol
yield
auc
use
crossvalid
second
microbiolog
confirm
subcohort
ntotal
nbacteri
nviral
ncontrol
yield
auc
ensur
conserv
perform
estim
generaliz
result
analysi
follow
focus
entir
studi
cohort
rather
unanim
microbiolog
confirm
subcohort
show
slightli
improv
perform
compar
perform
signatur
wellestablish
clinic
paramet
laboratori
measur
includ
white
blood
count
wbc
absolut
neutrophil
count
anc
percentag
neutrophil
maxim
temperatur
puls
respiratori
rate
fig
data
signatur
surpass
individu
paramet
p
next
compar
signatur
combin
clinic
paramet
develop
use
comput
techniqu
use
construct
signatur
best
perform
pair
triplet
quadruplet
depict
fig
ad
fifth
paramet
improv
perform
signatur
surpass
best
perform
combin
clinic
paramet
auc
vs
p
compris
anc
puls
lymphocyt
monocyt
next
compar
perform
signatur
procalcitonin
crp
two
protein
use
clinic
practic
diagnos
bacteri
infect
signatur
perform
significantli
better
protein
combin
p
p
p
respect
data
signatur
also
perform
better
wide
rang
hostprotein
establish
role
immun
respons
infect
includ
bacterialrel
eg
trem
virusrel
eg
inflammationrel
eg
protein
p
fig
data
mani
diseasecaus
bacteria
also
part
natur
flora
frequent
found
asymptomat
subject
bacteria
pose
consider
diagnost
challeng
mere
detect
necessarili
impli
caus
role
diseas
therefor
appropri
treatment
may
remain
unclear
accordingli
ask
whether
perform
signatur
affect
presenc
colon
streptococcu
pneumonia
sp
haemophilu
influenza
hi
detect
pcr
nasal
swab
two
common
bacteria
found
studi
group
tabl
high
rate
sp
hi
observ
amongst
bacteri
viral
patient
sp
hi
substanti
understand
mere
presenc
necessarili
caus
diseas
stratifi
patient
base
whether
sp
sp
nbacteri
nviral
sp
nbacteri
nviral
compar
auc
perform
two
group
observ
signific
differ
vs
p
presenc
absenc
hi
affect
signatur
perform
either
vs
hi
nbacteri
nviral
hi
nbacteri
nviral
p
indic
signatur
unaffect
potenti
carriag
sp
hi
hostprotein
signatur
present
address
sever
challeng
current
microbiolog
test
difficulti
diagnos
patient
whose
infect
site
inaccess
unknown
signatur
accur
diagnos
case
includ
lrti
auc
n
fever
without
sourc
auc
n
ii
prolong
time
result
hour
day
signatur
measur
solubl
protein
quantit
use
elisa
format
moreov
protein
readili
amen
rapid
measur
within
minut
use
hospitaldeploy
autom
immunoassay
machin
pointofcar
devic
iii
identif
viru
exclud
possibl
mix
infect
involv
undetect
bacteria
signatur
classifi
mix
infect
pure
bacteri
infect
thu
prompt
physician
manag
group
similarli
regard
antibiot
treatment
iv
signific
drawback
microbiolog
test
pcr
particular
detect
potenti
colon
subject
nonbacteri
diseas
signatur
perform
unaffect
presenc
absenc
potenti
colon
protein
includ
signatur
limit
wellestablish
bacteri
biomark
six
hundr
hostprotein
screen
fig
best
knowledg
largest
quantit
proteom
screen
patient
acut
infect
date
bioinformat
analysi
use
identifi
combin
three
protein
complementari
dynam
found
trail
induc
respons
wide
rang
viral
infect
surprisingli
also
exhibit
significantli
reduc
level
bacteri
infect
patient
fig
oppos
dynam
make
trail
particularli
suitabl
distinguish
bacteri
viral
infect
increas
viral
patient
may
relat
trail
role
program
cell
death
mechan
infect
cell
inhibit
viru
spread
underli
reason
reduct
bacteri
infect
warrant
studi
ii
level
highli
elev
viral
patient
less
elev
bacteri
patient
fig
iii
crp
level
highli
elev
bacteri
patient
less
elev
viral
patient
fig
util
increas
crp
level
suggest
bacteri
infect
well
establish
viralinduc
protein
trail
use
clinic
practic
combin
novel
viralinduc
protein
complement
routin
use
bacterialinduc
protein
substanti
contribut
signatur
robust
across
wide
rang
subgroup
current
singl
perfect
refer
standard
diagnos
bacteri
viral
infect
larg
fraction
patient
symptom
acut
infect
sever
strategi
appli
strength
limit
clinic
suspicion
confirm
posit
microbiolog
lab
result
often
use
refer
standard
howev
limit
includ
falseposit
due
technic
issu
eg
cultur
contamin
uncertainti
due
viral
bacteri
carriag
moreov
patient
may
repres
sever
ill
potenti
easier
diagnos
case
lead
overli
optimist
perform
expert
panel
diagnosi
anoth
wide
use
approach
advantag
captur
wider
spectrum
ill
sever
includ
difficulttodiagnos
case
therefor
like
gener
well
clinic
practic
howev
absenc
microbiolog
confirm
may
lead
higher
rate
mislabel
sinc
method
complement
appli
microbiolog
confirm
refer
standard
use
proofofprincipl
subcohort
patient
yield
particularli
high
perform
auc
expert
panel
refer
standard
use
gener
result
entir
patient
cohort
auc
latter
result
conserv
like
repres
perform
signatur
real
clinic
set
potenti
limit
current
studi
heterogen
patient
cohort
multipl
clinic
syndrom
pathogen
speci
time
onset
symptom
deliber
select
divers
cohort
order
identifi
signatur
insensit
interpati
variabl
typic
encount
clinic
set
howev
divers
make
challeng
control
confound
factor
although
identifi
signific
confound
followup
studi
homogen
subgroup
warrant
final
present
signatur
broader
applic
beyond
scope
present
studi
warrant
investig
futur
studi
seek
replic
find
patient
differ
ethnic
popul
particularli
countri
high
preval
endem
chronic
pathogen
eg
mycobacterium
tuberculosi
plasmodium
hiv
followup
time
cours
studi
assess
whether
signatur
predict
respons
treatment
patient
prognosi
also
warrant
despit
advanc
infecti
diseas
diagnosi
time
identif
bacteri
infect
remain
challeng
lead
antibiot
misus
profound
health
econom
consequ
address
need
better
treatment
guidanc
develop
valid
signatur
combin
novel
tradit
hostprotein
differenti
bacteri
viral
infect
find
larg
sampl
size
patient
promis
translat
benefit
could
broad
impact
diagnosi
manag
patient
acut
infect
